OTCMKTS:PFSCF ProMetic Life Sciences (PFSCF) Stock Price, News & Analysis $5.47 0.00 (0.00%) As of 11/18/2019 Add Compare Share Share Stock Analysis Stock Analysis About ProMetic Life Sciences Stock (OTCMKTS:PFSCF) Get ProMetic Life Sciences alerts:Sign Up Key Stats Today's Range$5.47▼$5.4750-Day Range$5.47▼$5.4752-Week Range$5.47▼$352.00VolumeN/AAverage Volume279 shsMarket Capitalization$127.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ProMetic Life Sciences Inc. was a Canadian biopharmaceutical company focused on developing and manufacturing plasma-derived therapeutics and other biologic products. Its technology platform was designed to purify proteins from human plasma and other biological materials, supporting the development of treatments for rare diseases and conditions involving deficiencies in specific plasma proteins. The company’s product portfolio and development programs included plasminogen replacement therapy, as well as investigational plasma-derived products for immune, blood, and liver-related disorders. ProMetic also provided biopharmaceutical manufacturing and purification capabilities through its proprietary affinity chromatography technologies. ProMetic operated internationally, with activities and partnerships spanning North America and Europe. The company was led for many years by Pierre Laurin, its founder, president, and chief executive officer. In 2019, ProMetic Life Sciences changed its name to Liminal BioSciences Inc., reflecting a broader focus on plasma-derived therapeutics and drug development.AI Generated. May Contain Errors. Read More Receive PFSCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProMetic Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PFSCF Stock News HeadlinesThere's Been No Shortage Of Growth Recently For TMC Life Sciences Berhad's (KLSE:TMCLIFE) Returns On CapitalJanuary 28, 2023 | finance.yahoo.comIndia's Glenmark Life Sciences Q3 profit rises 1% on API strengthJanuary 28, 2023 | reuters.comUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares still trade under 1 dollar. It just signed the largest transaction in its history, a new gold streaming deal backed by a strategic relationship with a major mining investment firm. A well-known sector financier has invested his own money and joins the CEO in an exclusive interview breaking down the full story.October 16 at 1:00 AM | Digest Publishing (Ad)Here's what to expect from Prometic Life Sciences's earnings reportMay 10, 2022 | markets.businessinsider.comSee More Headlines PFSCF Stock Analysis - Frequently Asked Questions How have PFSCF shares performed this year? ProMetic Life Sciences' stock was trading at $5.4670 at the beginning of the year. Since then, PFSCF shares have increased by 0.0% and is now trading at $5.4670. What other stocks do shareholders of ProMetic Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProMetic Life Sciences investors own include ProMetic Life Sciences (PLI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Canopy Growth (CGC), Conatus Pharmaceuticals (CNAT), Genocea Biosciences (GNCA) and ADMA Biologics (ADMA). Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:PFSCF Previous SymbolNASDAQ:PFSCF CIKN/A Webliminalbiosciences.com Phone1-450-781-0115FaxN/AEmployees50Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$150.73 million Net Margins-894.02% Pretax MarginN/A Return on Equity-3,350.55% Return on Assets-67.76% Debt Debt-to-Equity RatioN/A Current Ratio0.95 Quick Ratio0.71 Sales & Book Value Annual Sales$36.55 million Price / Sales3.49 Cash FlowN/A Price / Cash FlowN/A Book Value($67.63) per share Price / Book-0.08Miscellaneous Outstanding Shares23,313,000Free FloatN/AMarket Cap$127.45 million OptionableNot Optionable Beta2.46 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:PFSCF) was last updated on 11/18/2019 by MarketBeat.com Staff. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredSpaceX minted 4400 millionaires in a single daySpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredThis high yielding “gold annuity” is starting to move…Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProMetic Life Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProMetic Life Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.